Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
ANI Pharmaceuticals Inc is a drug manufacturers-specialty & generic business based in the US. ANI Pharmaceuticals shares (ANIP) are listed on the NASDAQ and all prices are listed in US Dollars. ANI Pharmaceuticals employs 369 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$38.08|
|52-week range||$23.55 - $40.00|
|50-day moving average||$32.87|
|200-day moving average||$32.97|
|Wall St. target price||$45.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.43|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||N/A|
|1 month (2021-09-24)||19.19%|
|3 months (2021-07-26)||14.42%|
|6 months (2021-04-26)||16.06%|
|1 year (2020-10-23)||31.54%|
|2 years (2019-10-25)||-51.22%|
|3 years (2018-10-25)||51.68|
|5 years (2016-10-25)||66.36|
Valuing ANI Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ANI Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
ANI Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.06. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into ANI Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
ANI Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $46.5 million.
The EBITDA is a measure of a ANI Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$213.4 million|
|Operating margin TTM||0.92%|
|Gross profit TTM||$125.6 million|
|Return on assets TTM||0.26%|
|Return on equity TTM||-8.99%|
|Market capitalisation||$470.4 million|
TTM: trailing 12 months
There are currently 501,853 ANI Pharmaceuticals shares held short by investors – that's known as ANI Pharmaceuticals's "short interest". This figure is 0.3% down from 503,219 last month.
There are a few different ways that this level of interest in shorting ANI Pharmaceuticals shares can be evaluated.
ANI Pharmaceuticals's "short interest ratio" (SIR) is the quantity of ANI Pharmaceuticals shares currently shorted divided by the average quantity of ANI Pharmaceuticals shares traded daily (recently around 65175.714285714). ANI Pharmaceuticals's SIR currently stands at 7.7. In other words for every 100,000 ANI Pharmaceuticals shares traded daily on the market, roughly 7700 shares are currently held short.
However ANI Pharmaceuticals's short interest can also be evaluated against the total number of ANI Pharmaceuticals shares, or, against the total number of tradable ANI Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ANI Pharmaceuticals's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 ANI Pharmaceuticals shares in existence, roughly 40 shares are currently held short) or 0.0604% of the tradable shares (for every 100,000 tradable ANI Pharmaceuticals shares, roughly 60 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against ANI Pharmaceuticals.
Find out more about how you can short ANI Pharmaceuticals stock.
We're not expecting ANI Pharmaceuticals to pay a dividend over the next 12 months.
ANI Pharmaceuticals's shares were split on a 1:6 basis on 17 July 2013. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ANI Pharmaceuticals shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for ANI Pharmaceuticals shares which in turn could have impacted ANI Pharmaceuticals's share price.
Over the last 12 months, ANI Pharmaceuticals's shares have ranged in value from as little as $23.55 up to $39.9999. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ANI Pharmaceuticals's is 1.1884. This would suggest that ANI Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
ANI Pharmaceuticals, Inc. , a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota. .
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.